concept · intermediate · partly written
Lipid nanoparticles
A lipid nanoparticle is a fat bubble that stays nearly neutral in blood and turns positively charged inside the acidic endosome, and it is used to deliver nucleic acids such as siRNA and mRNA.
Also called: LNP
The short version
A lipid nanoparticle carries RNA that is too large and charged to cross a membrane. Its ionisable lipid is neutral in blood and charged in the endosome. Blood ApoE steers it to the liver. Most RNA is still lost after uptake. 123
Reported, not yet replicated
The pKa switch more
The ionisable lipid needs to be charged enough to bind RNA while the particle is made at acidic pH, nearly neutral at blood pH 7.4 because permanently charged lipids are toxic and cleared fast, and charged again as the endosome acidifies. A mouse study of 56 lipids found potency peaked when the apparent pKa was between 6.2 and 6.5. The proposed next step, that the charged lipid destabilises the endosomal membrane, is the usual interpretation; no primary paper proving it in cells was opened. Intramuscular dosing may favour a different window; that was seen only in a search summary and is not relied on. 14
Reported, not yet replicated
The ApoE route and the protein coat more
PEG-lipid sheds from the particle in blood, plasma ApoE binds, and liver cells with LDL receptors take the particle up as if it were a lipoprotein. In ApoE-knockout mice the liver effect of an ionisable LNP was essentially abolished. Changing the lipids changes the coat and the organ, but vitronectin as a lung route was tested only in cultured cells, so organ-by-coat is a correlation plus a proposal. A 2023 report that potency depended on ApoE but not the LDL receptor was seen only in a search summary. 256
Reported, not yet replicated
Entry is not delivery more
Uptake and expression can move in opposite directions. In HepG2 cells an ApoE coat raised uptake about 4 to 5-fold and lysosome co-localisation about 2.9-fold with no gain in mRNA expression, and vitronectin and C-reactive protein coats lowered expression by about 50 and 90 percent. One cell line, in vitro. 7
Reported, not yet replicated
Limits deep
The pKa window and ApoE dependence come from mouse intravenous liver studies. Reported anti-PEG antibody effects, human variation in ApoE or LDL-receptor, and the 6.6 to 6.9 intramuscular window were not verified. 12
Our inference
His picture more
He said: "I don't actually know all the delivery vehicles for a drug but it has to be manufactured to be inside of some sort of lipid carrier. Again what are the dynamics of this? I don't understand." For nucleic acids this is correct; see the delivery routes record for why it is not true of most drugs. 8
Amit's hypothesis
Plain answer
A lipid nanoparticle packs an RNA with four kinds of lipid: an ionisable lipid, cholesterol, a phospholipid and a small amount of PEG-lipid. The ionisable lipid is charged at the acidic pH used for mixing and nearly neutral in blood, then charged again in the acidifying endosome, which is meant to help the RNA escape. In blood, plasma ApoE coats the particle and routes it to liver cells; changing the lipids changes the protein coat and the organ. Most of the RNA still does not reach the cytosol. 2163
Reported, not yet replicated
Why it matters
Equation
No single governing equation. The design variable is the apparent pKa of the ionisable lipid, with an optimum window for liver silencing in mouse; see the numbers.
Real numbers
What is in a marketed LNP
Per mL of Onpattro: 13.0 mg ionisable lipid DLin-MC3-DMA, 6.2 mg cholesterol, 3.3 mg DSPC (a phospholipid) and 1.6 mg PEG-lipid. FDA approval was announced by the company on 10 August 2018. The academic recipe was about 50 mol percent ionisable lipid, 10 phospholipid, 38.5 cholesterol and 1.5 PEG-lipid, particles 40 to 70 nm. 9102
Reported, not yet replicated
The pKa window
Of 56 amino lipids with pKa from 4.17 to 8.12, potency for liver factor VII silencing in mice peaked between 6.2 and 6.5. ED50 (mg siRNA/kg): MC3 (pKa 6.44) 0.03; a pKa 5.64 lipid 0.6; a pKa 6.93 lipid 0.15; MC3 in the tuned mix 0.005; in monkeys below 0.03. The authors call pKa necessary but not sufficient and note the trend may not hold for systems that do not use ApoE. 1
Reported, not yet replicated
Design history
A commentary reports siRNA ED50 falling from about 0.1 mg/kg in an unoptimised formulation to about 0.02 mg/kg with DLin-KC2-DMA; the original paper was not opened. 4
Reported, not yet replicated
The ApoE route
Adding ApoE raised LNP uptake about 6-fold at 0.1 micrograms/mL and 14-fold at 0.3, saturating near 20-fold; silencing was about 80 percent with ApoE and about 20 percent without. In ApoE-knockout mice liver silencing was essentially abolished and a GalNAc-PEG lipid restored it (ED50 about 0.02 mg/kg); in LDL-receptor-knockout mice it was greatly diminished but not abolished. Mouse, one paper. 2
Reported, not yet replicated
Other organs by changing the lipids
Adding 10 to 15 percent of a permanently cationic lipid moved expression from liver to spleen and, at 50 percent, to lung; Cre editing at 0.3 mg/kg reached about 40 percent of lung epithelial cells, 65 percent of lung endothelial cells and 93 percent of hepatocytes. The protein coat differed by organ: ApoE 13.3 percent of coat on liver particles, beta-2-glycoprotein I 20.1 percent on spleen, vitronectin 12.2 percent on lung. In ApoE-knockout mice liver activity fell 78 percent (standard) and 87 percent (liver-targeting). Vitronectin as the lung route was tested only in cultured cells. 56
Reported, not yet replicated
Escape and recycling
About 1 to 2 percent of siRNA reaches the cytosol, briefly; about 70 percent of what is taken up is exocytosed. Abstract-level. 311
Contested
In patients (label)
Onpattro: steady-state volume of distribution 0.26 L/kg, terminal half-life 3.2 +/- 1.8 days; infusion-related reactions in 19 percent versus 9 percent on placebo despite required premedication. 9
Reported, not yet replicated
Teach this
In one sentence
A lipid nanoparticle is neutral in blood and charged in the endosome, and its pKa window and its ApoE coat decide where it goes and how well it works. 12
Reported, not yet replicated
The five-minute version
Four lipids make the particle; the ionisable one has an apparent pKa near 6.2 to 6.5 in the best liver-silencing particles in mouse. In blood ApoE coats the particle and liver cells with LDL receptors take it up. Inside the cell about 1 to 2 percent of the RNA escapes the endosome and about 70 percent is exocytosed, so more uptake does not mean more expression. 12311
Reported, not yet replicated
What a listener will ask
Why does it go to the liver?
ApoE from plasma coats the particle and liver cells take it up as a lipoprotein; without ApoE in mice the effect was essentially abolished.
Can it go elsewhere?
Adding a different lipid shifted expression to spleen and lung in mice, with different protein coats.
Is higher uptake better?
The common wrong idea
If the particle gets into the cell the RNA has been delivered.
Most RNA stays in the vesicle or is expelled; only a few percent reach the cytosol. 12311
Reported, not yet replicated
The one citation to hand over: 2
Still open here
- Human data on ApoE and LDL-receptor dependence.
- The primary proof of the membrane-destabilising step in cells.
- Anti-PEG antibodies and complement reactions in patients: primary sources.
- Whether the escaping 1 to 2 percent is a special subpopulation.
Linked from
- Drug formulation and carriers not yet written
- Epigenome editing
- RNA interference
- Comirnaty (BNT162b2)
- CVnCoV (CureVac COVID-19 mRNA vaccine candidate)
- Patisiran (Onpattro)
- Gene therapy
- mRNA medicines and vaccines
- siRNA
- Daniel J. Siegwart
- Do people make antibodies to PEG on carriers, and do they clear the carrier faster?
Sources
- Jayaraman M, Ansell SM, Mui BL, Tam YK, et al.. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl (2012). paper; opened 2026-11-17 all records citing this
- Akinc A, Querbes W, De S, Qin J, et al.. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther (2010). paper; opened 2026-11-17 all records citing this
- Gilleron J, Querbes W, Zeigerer A, Borodovsky A, et al.. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol (2013). paper; opened 2026-11-17 all records citing this
- Liu Y, Huang L. Designer lipids advance systemic siRNA delivery. Mol Ther (2010). paper; opened 2026-11-17 all records citing this
- Cheng Q, Wei T, Farbiak L, Johnson LT, et al.. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol (2020). paper; opened 2026-11-17 all records citing this
- Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci U S A (2021). paper; opened 2026-11-17 all records citing this
- Voke E, Arral ML, Squire HJ, Lin TJ, et al.. Protein corona formed on lipid nanoparticles compromises delivery efficiency of mRNA cargo. Nat Commun (2025). paper; opened 2026-11-17 all records citing this
- Amit's dictation of 2026-11-17: what the atlas must contain. Kept in the atlas repository; not published.
- Onpattro (patisiran) lipid complex injection US prescribing information. Alnylam Pharmaceuticals (2025). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- FDA approves ONPATTRO (patisiran), announced 10 August 2018. Alnylam Pharmaceuticals investor relations (2018). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
- Sahay G, Querbes W, Alabi C, Eltoukhy A, et al.. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol (2013). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/concepts/lipid-nanoparticles.json